• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

EndoStim

EndoStim prepares FDA PMA submission for neurostim implant that treats GERD

January 4, 2023 By Sean Whooley

EndoStim announced today that it held a pre-submission meeting with the FDA regarding its implantable neurostimulation treatment for GERD. The pre-submission meeting comes in advance of a premarket approval (PMA) submission for the system. Santa Ana, California-based EndoStim designed it to treat drug-refractory gastroesophageal reflux disease (GERD). EndoStim received FDA breakthrough device designation for the […]

Filed Under: Business/Financial News, Food & Drug Administration (FDA), Implants, Neurological, Neuromodulation/Neurostimulation, Regulatory/Compliance Tagged With: EndoStim, FDA

EndoStim wins FDA breakthrough designation for EndoStim to treat drug-refractory GERD

October 26, 2022 By Sean Whooley

EndoStim announced that it received FDA breakthrough device designation for its neurostimulation system for treating GERD. Santa Ana, California-based EndoStim designed its system to treat drug-refractory gastroesophageal reflux disease (GERD). The disease affects the ring of muscle between the esophagus and the stomach, the lower esophageal sphincter (LES). It causes stomach acid to repeatedly flow […]

Filed Under: Food & Drug Administration (FDA), Neuromodulation/Neurostimulation, Regulatory/Compliance Tagged With: EndoStim, FDA

EndoStim adds $12m for neurostim GERD device

January 16, 2018 By Brad Perriello

EndoStim last week reported raising more than $12 million for its neurostimulation device for treating gastroesophageal reflux disease. The Dallas-based company hopes to bring in a total of $25 million in the round, which follows a $25 million Series D financing in May 2016. The most recent equity and options funding involved 20 unnamed investors, according to a […]

Filed Under: Funding Roundup, Neuromodulation/Neurostimulation, Wall Street Beat Tagged With: EndoStim

7 medtech stories we missed this week: June 23, 2017

June 23, 2017 By Danielle Kirsh

From Guardant suing Foundation Medicine to Interson receiving 510(k) clearance for ultrasound probes, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Guardant levels false advertising suit against Foundation Medicine Guardant Health announced in a June 22 press release that it has filed a lawsuit against Foundation Medicine […]

Filed Under: 510(k), Business/Financial News, Clinical Trials, Food & Drug Administration (FDA), Implants, Neurological, Regulatory/Compliance, Ultrasound Tagged With: EndoStim, Foundation Medicine Inc., Guardant Health, Interson, Lee's Pharmaceutical, Meditech, MedTech, Rythm, TSO3, Windtree Therapeutics

Skyline Medical CEO Kornberg steps down, Schwartz takes over as interim | Personnel Moves May 20, 2016

May 20, 2016 By Fink Densford

Skyline Medical CEO Kornberg steps down, Schwartz takes over as interim chief exec Skyline Medical said earlier this month that prez and CEO Joshua Kornberg has stepped away from his roles at the company, and is being replaced by Carl Schwartz who will serve as interim chief executive. Prior to his time at Skyline, Schwartz served […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7

Filed Under: Business/Financial News Tagged With: Battelle, EndoStim, LivaNova, Mauna Kea Technologies, Medtronic, NovoCure, Philips, Skyline Medical, Spirox, Volcano Corp.

EndoStim raises $25m Series D for neurostim GERD device

May 12, 2016 By Brad Perriello

Five months after spiking its plans for an initial public offering, EndoStim said today that it raised a $25 million Series D round for the neurostimulation device it’s developing to treat gastroesophageal reflux disease. Saint Louis- and Nijmegen, Holland-based EndoStim said Endeavour Vision led the round, joined by existing backer Santé Ventures and new investors Wellington Partners and Gimv. Endostim […]

Filed Under: Funding Roundup, Neuromodulation/Neurostimulation Tagged With: EndoStim, Gastrointestinal

EndoStim officially spikes $35m IPO

December 9, 2015 By Brad Perriello

EndoStim today officially spiked an initial public offering it hoped would raise $35 million for its neurostimulation device for gastroesophageal reflux disease. EndoStim, which had planned to put $10 million of the IPO’s proceeds into clinical studies and another $14 million to commercialize the system, tabled the offering in October 2014. Today the company filed a formal […]

Filed Under: Funding Roundup, Initial Public Offering (IPO), Neuromodulation/Neurostimulation Tagged With: EndoStim

Report: EndoStim tables IPO

October 24, 2014 By Brad Perriello Leave a Comment

Report: EndoStim tables IPO

EndoStim, citing poor market conditions, has tabled its initial public offering it hoped would raise nearly $36 million for its neurostimulation device for gastroesophageal reflux disease, according to Renaissance Capital.

EndoStim had planned to put $10 million of the IPO’s proceeds into clinical studies and another $14 million to commercialize the system.

Filed Under: Initial Public Offering (IPO), Neuromodulation/Neurostimulation, News Well Tagged With: EndoStim

EndoStim targets $36m IPO

October 1, 2014 By Alex Soule Leave a Comment

EndoStim targets $36m IPO

EndoStim said it hopes to raise nearly $36 million in an initial public offering, with plans to plow $10 million into clinical studies of its system to treat severe gastroesophageal reflux disease and another $14 million to commercialize the system.

Filed Under: Initial Public Offering (IPO), News Well, Wall Street Beat Tagged With: EndoStim, Otolaryngology/Ear, Nose & Throat (ENT)

Topera details $25M Series C round | Wall Street Beat

April 26, 2013 By Brad Perriello Leave a Comment

MassDevice.com Wall Street Beat

Topera said a new backer, New Enterprise Assoc., led a $25 million Series C round first reported by MassDevice.com last month, with an unnamed "strategic industry partner" joining the round.

Filed Under: Funding Roundup, News Well, Wall Street Beat Tagged With: Cardiac Rhythm Management, EndoStim, InVivo Therapeutics, Opko Health Inc., Pneuron Corp., Prolor Biotech, Sotera Wireless, Topera Medical

EndoStim takes funding round to $11M | Wall Street Beat

March 25, 2013 By Brad Perriello Leave a Comment

MassDevice.com Wall Street Beat

EndoStim added another tranche to its $16.5 million equity round, according to a regulatory filing, saying it’s added some $11.2 million to its coffers as it develops a pacemaker-like implant to treat gastro-esophageal reflux disease.

Filed Under: Funding Roundup, News Well, Wall Street Beat Tagged With: BioHeart, Clinical Trials, Echo Therapeutics Inc., EndoStim, Intuitive Surgical, Stereotaxis, Stryker

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy